World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 25 January 2021
Main ID:  NCT02770794
Date of registration: 11/05/2016
Prospective Registration: Yes
Primary sponsor: Chiba University
Public title: Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis OPTIWIT
Scientific title: Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity
Date of first enrolment: April 1, 2016
Target sample size: 211
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02770794
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 4
Countries of recruitment
Japan
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

1. 18 years or older

2. RA patients who fulfill 2010 ACR/EULAR Classification Criteria

3. Patients who have been treated with infliximab (Remicade) for 26 weeks or longer

4. DAS28 (CRP) < 3.2 at screening

5. Patients who give written informed consent after receiving sufficient information -

Exclusion Criteria:

1. Receiving prednisolone > 10 mg/day

2. Receiving biological or molecular-target anti-rheumatic drug

3. Alteration of the dose of corticosteroid or anti-rheumatic drug within 8 weeks prior
to screening visit

4. Alteration of the dose of non-steroid anti-inflammatory drug within 4 weeks prior to
screening visit

5. History of infusion reaction to infliximab

6. Current infection which requires treatment

7. Current or previous demyelinating disorder

8. Current congestive heart failure which requires treatment

9. Breast-feeding or pregnant/possibly pregnant woman, or woman who does not agree to
prevent conception during and 6 months after study period

10. Patients whom investigator or co-investigator consider inappropriate for other reasons
-



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Arthritis, Rheumatoid
Intervention(s)
Drug: Infliximab
Primary Outcome(s)
Area under the Receiver Operator Characteristic (ROC) curve for total power Doppler score to predict relapse [Time Frame: 48 week]
Secondary Outcome(s)
Area under the ROC curve for total gray-scale score to predict relapse [Time Frame: 48 week]
Change in EuroQoL 5 dimensions-5L [Time Frame: 48 week]
Change in Health Assessment Questionnaire-Disability Index [Time Frame: 48 week]
Change in van der Heijde modified Sharp score [Time Frame: 48 week]
EULAR response criteria based on DAS28 after readministration of infliximab [Time Frame: 12 week after relapse]
Number of adverse events as assessed by CTCAE v4.0 [Time Frame: Through study completion, an average of 60 weeks]
Secondary ID(s)
137
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history